As multinationals recalibrate their India operations, Indian pharmas eager to raise their game

1 March 2022

Are multinational pharmaceutical companies losing ground in India? The ongoing restructuring and overhaul taking place at several multinational drug companies based in India, including the sale of brands and the closing of non-core units, came up for discussion at a recent event, reports The Pharma Letter’s India correspondent.

Experts noted that many drug multinational companies appear to be selling off or ceasing to promote their established brands in India.

Citing the case of Novartis’ (NOVN: VX) Indian subsidiary selling three established brands to Dr Reddy's Laboratories (BSE: 500124) last month, and Eli Lilly (NYSE: LLY) selling off two of its best-selling diabetes brands, Humalog (insulin lispro) and Trulicity (dulaglutide), to Cipla (BSE: 500087) last October, industry stalwarts present at the recently concluded Bio Asia summit, debated the change in strategy being adopted by multinationals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK